Acetyl choline Receptor Antibody

A positive acetylcholine receptor (AChR) antibody test means the immune system is making antibodies that target ACh receptors at the neuromuscular junction. This strongly suggests autoimmune myasthenia gravis, explaining fluctuating muscle weakness and fatigue. It supports the diagnosis, may not correlate exactly with disease severity, and typically prompts neurologic evaluation and treatments like anticholinesterase drugs, immunosuppression, or thymus assessment.

Acetylcholine receptor (AChR) antibodies are primarily associated with autoimmune myasthenia gravis—both generalized and ocular forms—and with thymic abnormalities, including thymoma and thymic hyperplasia. Maternal AChR antibodies can cause transient neonatal myasthenia gravis. They help distinguish AChR-antibody–positive MG from other neuromuscular junction disorders, and testing guides diagnosis and treatment decisions.

High AChR usually means elevated acetylcholine‑receptor antibodies, indicating an autoimmune attack on neuromuscular junctions. This is most commonly seen in myasthenia gravis and causes fluctuating muscle weakness, eyelid droop, double vision, difficulty swallowing, speaking or breathing. A high result supports diagnosis; further neurologic evaluation and tests guide treatment with immunotherapy, acetylcholinesterase inhibitors, or thymic evaluation.

The acetylcholine receptor (AChR) antibody test is a blood test that detects antibodies targeting ACh receptors on muscle cells. A positive result supports a diagnosis of myasthenia gravis, especially in generalized cases; a negative result doesn’t exclude it, since other antibodies or tests may be involved. Results help guide treatment and prompt further testing such as MuSK antibody assays or electrodiagnostic studies.

For AChR‑antibody–positive myasthenia gravis, initial symptomatic therapy is pyridostigmine. Immunosuppression with corticosteroids is commonly started, adding steroid‑sparing agents (azathioprine, mycophenolate, cyclosporine) as needed. Rapid exacerbations or preoperative needs use IVIG or plasmapheresis. Thymectomy is recommended for thymoma and selected generalized cases. Refractory disease may respond to complement inhibition (eculizumab) or B‑cell–directed therapies.

To confirm myasthenia gravis, clinicians combine clinical exam (fluctuating muscle weakness) with tests: antibody blood tests (anti‑acetylcholine receptor, anti‑MuSK), electrophysiology (repetitive nerve stimulation, single‑fiber EMG), and bedside tests (ice‑pack for ptosis). Chest imaging (CT/MRI) checks for thymoma. Pulmonary function tests assess respiratory involvement. Multiple modalities are used to establish autoimmune neuromuscular transmission failure.